Free Trial

More results...

Filter by Content types
Regulatory databases
Regulatory reports
Market reports
News analysis
Filter by Geography
Africa
Asia
Australasia
Europe
United Kingdom
North America
United States
South America

Alerts LATEST ALERTS

  • Brazil Up to 0.3% THC in plants authorised for medical, pharmaceutical, industrial use ...
  • Australia Parliamentary committee makes suggestions for cannabis law in NSW ...
  • Australia Greens announce Parliament will vote on cannabis legalisation this month ...
  • Texas - United States Bills introduced in Senate and House on medical cannabis expansion ...
  • Texas - United States House bill introduced to regulate hemp production and require research permit ...
  • Texas - United States House bills introduced on legalising recreational cannabis ...
  • Lithuania - Ukraine Cannabis conference focuses on fibre hemp, addressing challenges, restrictions ...
  • Czech Republic Criminal law reform approved, will relax some cannabis-related laws ...
  • New Zealand First sublingual THC/CBD spray meets Medicinal Cannabis Agency quality standard ...
  • Poland Motion for cannabis decriminalisation presented to prime minister ...
  • Belgium Health Belgium updates notified herbal products for smoking list ...
  • Portugal Infarmed withdraws several CBD products from market ...
View all
News analysis

German pharma firm buys €80m C3 to boost its European cannabis presence

Written by || 26th January 2022 || News analysis | Companies | GeographiesCanada Europe Germany North America

This story examines the significance of German pharma group Dermapharm’s acquisition of the Germany based Cannabinoid Compound Company (C3) from Canadian owner Canopy Growth. We show how it’s an opportunity for Dermapharm to expand in the European medical cannabis market, but represents a considerable loss for Canopy after only three years’ ownership.

Read full article

Download the full news analysis

"*" indicates required fields

Name*
*
This field is for validation purposes and should be left unchanged.

I'm already a subscriber

Login

Author default picture

CannIntelligence

This article was written by one of CannIntelligence’s international correspondents. We currently employ more than 40 reporters around the world to cover individual cannabis and cannabinoid markets. For a full list, please see our Who We Are page.

Our Key Benefits

The global cannabis market is in an opaque regulatory environment that requires professionals to be on top of industry developments to make informed decisions and optimise their strategy.

CannIntelligence provides organisations with leading market and regulatory data analysis to anticipate and understand market developments globally and the impact of regulatory changes to the business.

  • Stay informed of any legal and market change in the sector that impacts your organisation
  • Maximise resources by getting market and legal data analysis daily in one place
  • Make smart decisions by understanding how the regulatory and market landscape evolves
  • Anticipate risks in your decisions by monitoring regulatory changes that impact your organization

Thanks for getting in touch with us

Please leave your enquiry and we will get back to you within 24 hours

"*" indicates required fields

Name*
*
This field is for validation purposes and should be left unchanged.

Sign up to our newsletter

Stay up-to-date with key market trends and regulatory news and receive complimentary data on a regular basis.

"*" indicates required fields

Name*
*
This field is for validation purposes and should be left unchanged.